Taysha Gene Therapies TSHA
NASDAQ TSHA
$5.61 +0.04 (+0.72%)
As of: Sep 4, 2026 · 3:59 PM EDT

Taysha Gene Therapies (TSHA) EV to FCF (2020 - 2026)

Analysis

Taysha Gene Therapies (TSHA) EV to FCF (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Taysha Gene Therapies 2.06 Bn 2.06 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -43.16
Mar 31, 2026 -33.29
Dec 31, 2025 -46.25
Sep 30, 2025 -35.37
Jun 30, 2025 -15.67
Mar 31, 2025 -11.49
Dec 31, 2024 -11.75
Sep 30, 2024 -17.65
Jun 30, 2024 -12.74
Mar 31, 2024 -20.68
Dec 31, 2023 -3.79
Sep 30, 2023 -12.98
Jun 30, 2023 0.14
Mar 31, 2023 0.53
Dec 31, 2022 0.92
Sep 30, 2022 -1.38
Jun 30, 2022 -2.03
Mar 31, 2022 -3.07
Dec 31, 2021 -6.11
Sep 30, 2021 -14.82